Skip to main content

Newborn Screening Market to Witness 6.8% CAGR by 2031 | SkyQuest Technology

The emergence of congenital disorders among newborns is projected to drive the growth rate in the newborn screening market.

Westford, USA, Dec. 04, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Newborn Screening Market size will attain the value of USD 2.12 Billion by 2031, with a CAGR of 6.8% during the forecast period (2024-2031). The rising neonatal population, increasing cases of congenital diseases in newborns and growing consumer awareness are factors estimated to propel newborn screening industry growth over the forecast period. In addition, technological advancements in screening methodologies are also expected to boost the market. These kinds of congenital anomalies consist of genetic disorders, hearing impairment, and metabolic issues. It is crucially important to diagnose such anomalies early because a proper intervention may sharply improve the quality of life and the desired outcome of the treatment for neonates suffering from these conditions.
Request your free sample copy of the report: https://www.skyquestt.com/sample-request/newborn-screening-market

Browse in-depth TOC on “Newborn Screening Market ”

  • Pages – 177
  • Tables – 89
  • Figures – 71

Newborn Screening Market Overview:

Report CoverageDetails
Market Revenue in 2023USD 1.25 Billion
Estimated Value by 2031USD 2.12 Billion
Growth RatePoised to grow at a CAGR of 6.8%
Forecast Period2024–2031
Forecast UnitsValue (USD Billion)
Report CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments CoveredProduct, Test, Technology, End User and Region
Geographies CoveredNorth America, Europe, Asia Pacific, and the Rest of the world
Report HighlightsAdvanced Genetic Testing Integration
Key Market OpportunitiesGlobal Expansion of Newborn Screening Program
Key Market DriversIncreased Awareness of Genetic Disorders

Newborn Screening Market Segmental Analysis
Global Newborn Screening Market is segmented by Product, Test, technology, end user and region.
Based on Product, the market is segmented into Consumables, Instruments, Hearing screening instruments, Pulse oximeters.
Based on Test, the market is segmented into Dry blood spot tests, Hearing screening tests, CCHD screening tests.
Based on technology, the market is segmented into Immune assays & enzymatic assays, Tandem mass spectrometry, Molecular assays, Hearing screening technologies, Pulse oximetry, Other Technologies.
Based on end user, the market is segmented into Clinical Laboratories, Hospitals.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Instruments Segment to Dominate Due to Increasing Newborn Screening Programs

As per newborn screening market outlook, the instruments segment accounted for the largest market share of 75.91%. This segment has the potential for the highest compound annual growth rate during the forecast period. Key factors in this segment include increasing newborn screening programs, widespread awareness among people about the importance of early diagnosis and greater investment in newborn screening. Another factor driving the growth of this segment is technological advancement. This is highlighted in the fact that GC Labs has just recently started offering a new diagnostic test for Inborn Errors of Metabolism (IEM) in neonates, incorporating improved techniques for the detection of diseases.

Hearing Screening Technologies Segment is Growing Due to Increased Incidence of Birth Defects in Infants

The hearing screening technologies segment is expected to grow during the forecast period. Increased incidence of birth defects in infants and congenital hearing loss is predicted to drive hearing screens segment during the forecast period to a high compound annual growth rate. As per a 2023 study carried out by the University of Manchester, among every 1000 babies born in the UK, one suffered from birth impairment, hearing. The newborn screening market growth can be attributed to technological advances in hearing testing through automated auditory brainstem response (AABR) and otoacoustic emission (OAE), enabling accurate and rapid diagnosis of infant hearing problems.
For a tailored report, contact us to request a free customization: https://www.skyquestt.com/speak-with-analyst/newborn-screening-market

Asia Pacific is Dominating Due to Better Healthcare Services

As per newborn screening market analysis, Asia Pacific had the largest share in the market. This leadership comes from new growth prospects with better healthcare services and infrastructure. Methods of newborn screening are due to high birth rate, population growth and increasing incidence of birth defects in the region. Government policy and expenditure on health facilities is predicted to push the market further.
Drivers

  • Growing Prevalence of Congenital Abnormalities
  • Governmental Initiatives and Compulsory Screening Programs
  • Increased Awareness of Genetic Disorders

Restraints

  • Expensive Cost of Newborn Screening Tests
  • False Positive Results and Parental Stress
  • Lack of Standardization

Prominent Players in Newborn Screening Market

  • Masimo Corp.
  • Covidien Plc
  • AB Sciex LLC
  • Natus Medical Inc.
  • Agilent Technologies Inc.
  • PerkinElmer Inc.
  • GE Healthcare
  • Bio-Rad Laboratories Inc.
  • Trivitron Healthcare
  • Medtronic Inc.
  • Rady Children’s Institute for Genomic Medicine
  • GE Lifesciences
  • Waters Corporation
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • VIVOSONIC
  • ZIVAK TECHNOLOGIES
  • CAMAG
  • OTODYNAMICS
  • ZENTECH

Purchase now to gain valuable insights and stay informed: https://www.skyquestt.com/buy-now/newborn-screening-market

Key Questions Answered in Newborn Screening Market Report

  • Who are the key players in the market?
  • Which is the fastest growing region in the market?
  • What years does this market cover, and what was the market size in 2023?

This report provides the following insights:
Analysis of key drivers (governmental initiatives and compulsory screening programs), restraints (expensive cost of newborn screening tests), opportunities (advanced genetic testing integration) influencing the growth of Newborn Screening Market.

  • Market Dynamics: Comprehensive information about the various products offered by the dominant players in the Newborn Screening Market.
  • Product Development/Innovation: An overview of emerging trends, R&D activities and product launches in the Newborn Screening Market.
  • Market Growth: Detailed information on profitable growing industries.
  • Market Trends: Complete information about new products, emerging geographical areas and recent developments in the market.
  • Competitive Analysis: An in-depth analysis of the market segments, growth strategies, revenue analysis, and products of the key market players.

To read the full report, please visit: https://www.skyquestt.com/report/newborn-screening-market

Related Reports:
Rare Disease Treatment Market Set to Grow at 12.8% CAGR Through 2031
Intravenous Solutions Market Set to Grow at 8.0% CAGR Through 2031
Pet Accessories Market Set to Grow at 7.5% CAGR Through 2031
Rhinoplasty Implants Market Set to Grow at 7.0% CAGR Through 2031
Atrial Fibrillation Market Set to Grow at 11.96% CAGR Through 2031
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact:
Mr. Jagraj Singh
Skyquest Technology
1 Apache Way,
Westford,
Massachusetts 01886
USA (+1) 351-333-4748
Email: sales@skyquestt.com
Visit Our Website: https://www.skyquestt.com/

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.